Gilead Sciences Inc

This is an advisory 'say-on-pay' proposal asking stockholders to approve the compensation disclosed for Gilead’s Named Executive Officers. Management seeks shareholder support to validate its 2025 pay decisions, which emphasize a pay-for-performance philosophy with a significant portion of pay at risk and tied to multi-year performance shares, stock options and annual incentives weighted toward financial and strategic metrics. The Compensation and Talent Committee points to a rigorous annual incentive design (60% financial, 40% strategic), long-term performance shares tied to relative TSR and adjusted EPS growth, and clawback and governance policies as evidence of alignment with stockholders. Management also highlights strong recent business performance (record HIV sales, pipeline progress) and substantial shareholder returns as contextual justification for realized pay outcomes. The vote is non-binding, but the Board states it will consider results when setting future compensation. Opposition would generally reflect investor concern about pay quantum, incentive metrics, or governance, while support signals approval of pay design and outcomes. Given Gilead’s prior 91% support in 2025 and the Board’s emphasis on alignment and shareholder engagement, management frames the proposal as consistent with long-term value creation. The Board recommends FOR to endorse the program’s balance of short- and long-term incentives and retention value; however, investors will weigh the structure and realized payouts versus underlying performance and risks when casting their advisory ballots.

This management proposal requests stockholder approval to amend and restate Gilead’s 2022 Equity Incentive Plan to add 47.75 million shares to the reserve and extend the plan term to March 11, 2036. Management frames the request as necessary to preserve a comprehensive equity compensation program that attracts, retains and incentivizes critical talent across the business, thereby supporting long-term stockholder value. The Compensation and Talent Committee reviewed historical burn rates, projected future equity needs, dilution (overhang) and sought independent advice from its external consultant; the filing discloses a three-year average adjusted gross burn rate near 1.1% and describes governance features (no repricing without stockholder approval, minimum vesting, limits on non-employee director compensation, clawback policies, double-trigger change-in-control treatment). Management also details share-counting rules, fungible share treatment for full-value awards, and adjustments for forfeitures and cancellations to limit liberal recycling. The board argues the plan includes robust protective provisions and is designed to balance talent incentives with shareholder protections, while disclosing the anticipated post-approval share reserve and dilution metrics. Opponents typically focus on incremental dilution and ask for more conservative share requests or stricter limits; proponents emphasize the operational need to grant competitive equity awards for retention and performance alignment. The Board recommends FOR based on benchmarking, governance enhancements, and its view that the A&R 2022 Plan aligns award opportunity with long-term shareholder interests.

The proponent (John Chevedden) asks Gilead to adopt a policy separating the roles of Chair and CEO and to require the Chair be an independent director, arguing independent chairs improve oversight and reduce conflicts. Management counters that past stockholder votes have rejected similar proposals, that the Board needs flexibility to select leadership tailored to Gilead’s circumstances, and that a robust Lead Independent Director role (currently Anthony Welters) provides independent oversight comparable to an independent chair. The dispute is rooted in governance philosophy: proponents emphasize formal separation to strengthen checks and balances after legal and operational controversies, while the Board emphasizes continuity, CEO leadership benefits during strategy execution, and mechanisms (independent committees, lead director, evaluations) that it says provide sufficient independent oversight. The issue implicates stockholder confidence, board effectiveness, CEO accountability, succession planning, and potential impacts on decision-making efficiency during major strategic initiatives. Investors evaluating the proposal will weigh the credibility of the Board’s independent lead director framework, historical stockholder voting patterns, recent governance developments, and any company-specific governance incidents cited by proponents. A vote FOR signals preference for structural separation as a governance best practice; a vote AGAINST reflects confidence in the Board’s current structure and its ability to adapt leadership when appropriate. The Board recommends AGAINST, citing investor engagement, its Lead Independent Director charter, and perceived benefits of flexibility.

The AHF proposal requests a public report analyzing how patent extensions could delay biosimilars and novel therapeutics and thereby harm patient access, citing historical allegations around Truvada/Descovy timing and related litigation as an example. Management counters that patents incentivize innovation, that Gilead runs broad access programs (tiered pricing, voluntary licensing, Global Fund partnerships) and that the Board already oversees product development and access; it views the report as unnecessary and potentially biased. The core of the debate is the tradeoff between IP-driven returns that fund R&D versus public-health concerns about access and potential strategic timing of product rollouts. Analysts will evaluate the company’s historical conduct, licensing practices, and disclosed access commitments alongside legal and reputational risks. Supporters of the proposal seek transparency and an independent risk assessment to inform governance and investment decisions; opponents argue such reporting duplicates existing oversight and could divert resources. The Board recommends AGAINST, stressing incentives for innovation and detailed descriptions of existing access initiatives, while proponents will emphasize prior settlements and public criticism to argue for independent assessment.

The Bahnsen Family Trust (via Bowyer Research) requests an assessment of risks tied to including ESG and DEI metrics in executive pay, arguing such metrics are subjective, legally risky, and dilute financial focus. Management responds that Gilead’s compensation program is predominantly pay-for-performance, with financial metrics weighted 60% and employee engagement/inclusion representing a limited portion (10%) of the annual incentive; it further emphasizes governance oversight by the Compensation and Talent Committee and broad stockholder support for current pay practices. The controversy centers on balancing non-financial objectives (talent, culture, stakeholder expectations) with fiduciary obligations to maximize shareholder value and avoid regulatory or reputational risk. Proponents favor transparency regarding how DEI/ESG goals are defined, measured and linked to business outcomes; opponents argue a formal report would be duplicative and resource-consuming given existing disclosure, oversight, and limited use of people metrics. Investors will assess whether current disclosures and oversight suffice or whether an independent risk assessment could materially inform governance decisions. The Board recommends AGAINST, citing existing controls, limited weighting for such metrics, and active shareholder engagement demonstrating strong support for current practices.